| |
(n = 54)
|
---|
Age (median)
| |
57 years
|
Gender
|
Female
|
54 (100%)
|
Race
|
Asian
|
4 (7%)
|
|
Black
|
4 (7%)
|
|
Hispanic
|
1 (2%)
|
|
White
|
33 (61%)
|
|
Other/unknown
|
12 (22%)
|
Grade
|
0
|
1 (2%)
|
|
1
|
1 (2%)
|
|
2
|
14 (26%)
|
|
3
|
21 (39%)
|
|
Unknown
|
17 (31%)
|
Histology
|
IDC*
|
48 (76%)
|
|
ILC
|
3 (5%)
|
|
Unknown
|
12 (19%)
|
Estrogen receptor
|
Positive( +)
|
22 (41%)
|
|
Negative (−)
|
27 (50%)
|
|
Unknown
|
5 (9%)
|
Progesterone receptor
|
Positive ( +)
|
13 (24%)
|
|
Negative (-)
|
37 (69%)
|
|
Unknown
|
4 (7%)
|
HER2 receptor
|
Positive ( +)
|
11 (20%)
|
|
Negative (−)
|
40 (74%)
|
|
Unknown
|
3 (6%)
|
TNBC
| |
20 (37%)
|
CAMLs present
| |
53 (98%)
|
Average CAMLs per patient
|
5 CAMLs
| |
CTCs present
| |
34 (63%)
|
Average CTCs per patient
| |
4 CTCs
|
Average prior therapies
| |
3
|
- Number of average prior therapies was calculated using patients with a confirmed number of prior therapies. *9 IDC patients were of the IBC subtype